Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review

被引:9
|
作者
Lopez-Lopez, Jose P. [1 ,2 ]
Gonzalez, Ana Maria [1 ]
Lanza, Paola [1 ]
Lopez-Jaramillo, Patricio [1 ,3 ]
机构
[1] Univ Santander UDES, MASIRA Res Inst, Bucaramanga, Santander, Colombia
[2] Pontificia Univ Javeriana, Hosp Univ San Ignacio, Dept Internal Med, Cardiol Unit, Bogota, Colombia
[3] Univ Santander UDES, MASIRA Res Inst, Fac Ciencias Salud, Bloque G,Piso 6, Bucaramanga, Santander, Colombia
关键词
polypill; cardiovascular disease; hypertension; dyslipidemia; major cardiovascular events; DOSE COMBINATION TREATMENT; HIGH-RISK; BLOOD-PRESSURE; STRATEGY; TRIAL; DRUGS;
D O I
10.2147/VHRM.S421024
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Higher medication adherence reduces the risk of new cardiovascular events. However, there are individual and health system barriers that lead to lower adherence. The polypill has demonstrated benefits in cardiovascular morbidity and mortality mainly driven by an increase in adherence. We aim to evaluate the impact of the polypill on adherence to cardiovascular medication, its efficacy and safety in cardiovascular disease (CVD) prevention. Methods: A systematic review following PRISMA guidelines was conducted. Databases were searched from January 2003 to December 2022. We included randomized, pragmatic, or real-world clinical trials and observational studies. The primary outcome was medication adherence, secondary outcomes were efficacy in cardiovascular disease in primary and secondary prevention and safety. Results: From the 490 publications screened, 13 met the inclusion criteria and were incorporated into a comparative table Of those included, 70% were randomized controlled trials (RCTs) and 53.8% focused on secondary prevention. Most of the studies received a high and moderate quality rating. Self-report, pill counting and, the Morisky scale were the most frequent methods to evaluate adherence (84.6%). Compared with standard medication, the polypill improved overall medication adherence by 13%, with percen-tages ranging from 7.6% to 34.9%. Moreover, a potential benefit was also observed in reducing Major Adverse Cardiovascular Events (MACE), particularly in secondary prevention studies, with hazard ratios ranged between 0.43 to 0.76. Compared to standard care, the profile of side effects was similar. Conclusion: The polypill is an effective, safe, and practical strategy to improve adherence in people at risk of CVD. Although there is a demonstrated benefit in reducing MACE, predominantly in secondary prevention, there are still gaps in its efficacy in primary prevention and reducing total mortality. Therefore, the importance of obtaining long-term results of the polypill effect and how this strategy can be implemented in real practice.
引用
收藏
页码:605 / 615
页数:11
相关论文
共 50 条
  • [1] Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials
    Mohamed, Mohamed M. G.
    Osman, Mohammed
    Kheiri, Babikir
    Saleem, Maryam
    Lacasse, Alexandre
    Alkhouli, Mohamad
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 360 : 91 - 98
  • [2] Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management
    Narita, Keisuke
    Hoshide, Satoshi
    Kario, Kazuomi
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [3] Role of the polypill for secondary prevention in ischaemic heart disease
    Castellano, Jose M.
    Fuster, Valentin
    Jennings, Catriona
    Prescott, Eva
    Bueno, Hector
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 : 44 - 51
  • [4] Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review
    Jahangiri, Reza
    Rezapour, Aziz
    Malekzadeh, Reza
    Olyaeemanesh, Alireza
    Roshandel, Gholamreza
    Motevalian, Seyed Abbas
    PLOS ONE, 2022, 17 (07):
  • [5] The polypill in the primary prevention of cardiovascular disease
    Wald, David S.
    Wald, Nicholas J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (01) : 29 - 35
  • [6] Female participation, and sex-specific reporting practices, in polypill randomized controlled trials in the prevention of atherosclerotic cardiovascular disease: a secondary analysis of a systematic review
    Peters, Sanne A. E.
    Rodgers, Anthony
    Patel, Anushka
    Norton, Robyn
    Huffman, Mark D.
    Agarwal, Anubha
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024,
  • [7] A Polypill for All? Critical Review of the Polypill Literature for Primary Prevention of Cardiovascular Disease and Stroke
    Carey, Katherine M.
    Comee, Morgan R.
    Donovan, Jennifer L.
    Kanaan, Abir
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (05) : 688 - 695
  • [8] Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill
    Lafeber, M.
    Spiering, W.
    Visseren, F. L. J.
    Grobbee, D. E.
    CURRENT HYPERTENSION REPORTS, 2016, 18 (05)
  • [9] The polypill strategy in cardiovascular disease prevention: It's time for its implementation
    Di Fusco, Stefania Angela
    Aquilani, Stefano
    Spinelli, Antonella
    Alonzo, Alessandro
    Matteucci, Andrea
    Castello, Lorenzo
    Imperoli, Giuseppe
    Colivicchi, Furio
    PROGRESS IN CARDIOVASCULAR DISEASES, 2023, 79 : 37 - 40
  • [10] The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis
    Salim, Hamza
    Musmar, Basel
    Saifi, Motaz
    Ayyad, Mohammed
    Ruzieh, Mohammed
    Azar, Jehad
    Nazzal, Zaher
    CURRENT CARDIOLOGY REVIEWS, 2024, 20 (02) : 61 - 71